Literature DB >> 16408368

Bevacizumab and erlotinib show promise for kidney cancer.

Heather Lindsey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16408368     DOI： 10.1016/s1470-2045(05)70521-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Molecular targets and targeted therapies in bladder cancer management.

Authors:  Ramy F Youssef; Anirban P Mitra; Georg Bartsch; Peter A Jones; Donald G Skinner; Richard J Cote
Journal:  World J Urol       Date:  2008-11-28       Impact factor: 4.226

2.  Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.

Authors:  Jeffrey A Meyerhardt; Marek Ancukiewicz; Thomas A Abrams; Deborah Schrag; Peter C Enzinger; Jennifer A Chan; Matthew H Kulke; Brian M Wolpin; Michael Goldstein; Lawrence Blaszkowsky; Andrew X Zhu; Meaghan Elliott; Eileen Regan; Rakesh K Jain; Dan G Duda
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

3.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.